If pharma wants to help the NHS improve outcomes, it needs to do so through a true partnership rather than a transactional relationship. That’s according to Daiichi Sankyo’s UK managing ...

Sharp took over operations at the 146,000-square-foot plant and is now packaging several of Daiichi’s medications. Sharp said it has offered the plant’s workers opportunities for employment.

Daiichi Sankyo and partner AstraZeneca’s Enhertu previously wowed industry watchers with stellar clinical data in heavily pretreated breast cancer, leading to a speedy FDA nod at the end of 2019.

The antibody-drug conjugate (ADC) market is emerging as one of the most competitive areas in pharma, with companies ... analysts at GlobalData expect Daiichi Sankyo to dominate the space through ...

Mumbai-headquartered Sun Pharma, India's largest drugmaker by sales, agreed to buy Ranbaxy from Daiichi Sankyo for $3.2 billion in April 2014 . As part of that deal, Daiichi Sankyo got a 8.9 ...

Daiichi Sankyo said today it has sold off the 8.9% stake in Sun Pharmaceutical Industries it inherited when Sun Pharma agreed to buy Ranbaxy from Daiichi Sankyo last year. Daiichi Sankyo raised $3 ...

Additional Data and Trials-in-Progress Across Daiichi Sankyo’s DXd ADC Portfolio at ASCO Additional sub-analyses from the TROPION-Lung02 phase 1b trial (#8617) evaluating datopotamab deruxtecan ...

TOKYO and LONDON Daiichi Sankyo has agreed to purchase the German biotech company U3 Pharma for $233.5 million, in an effort to boost its cancer drug pipeline, according to Reuters. The company ...

Follow-on collaboration between ViGeneron and Daiichi Sankyo allows the companies to create and validate ... where an AAV2-based peptide-display library was intravenously administered in mouse models ...

Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 20 abstracts in multiple cancers at the 2025 American Society of Clinical Oncology ...

If pharma wants to help the NHS improve outcomes, it needs to do so through a true partnership rather than a transactional relationship. That’s according to Daiichi Sankyo’s UK managing ...

Mumbai-headquartered Sun Pharma, India's largest drugmaker by sales, agreed to buy Ranbaxy from Daiichi Sankyo for $3.2 billion in April 2014 . As part of that deal, Daiichi Sankyo got a 8.9 ...